Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V, Galazi M, Weitsman G, Monypenny J, Al-Salemee F, Barber PR, Ng K, Beatson R, Szokol B, Orfi L, Mullen G, Vanhaesebroeck B, Chowdhury S, Leung HY, Ng T. Gómez V, et al. Among authors: orfi l. Mol Cancer Ther. 2022 Apr 1;21(4):667-676. doi: 10.1158/1535-7163.MCT-21-0320. Mol Cancer Ther. 2022. PMID: 35086953 Free PMC article.
Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.
Dolman ME, Harmsen S, Pieters EH, Sparidans RW, Lacombe M, Szokol B, Orfi L, Kéri G, Storm G, Hennink WE, Kok RJ. Dolman ME, et al. Among authors: orfi l. Int J Nanomedicine. 2012;7:417-33. doi: 10.2147/IJN.S26485. Epub 2012 Jan 31. Int J Nanomedicine. 2012. PMID: 22334775 Free PMC article.
[Developing FGFR inhibitors as potential anti-cancer agents].
Zsákai L, Németh G, Szántai-Kis C, Greff Z, Horváth Z, Szokol B, Baska F, Boon TC, Orfi L, Kéri G. Zsákai L, et al. Among authors: orfi l. Acta Pharm Hung. 2013;83(2):47-56. Acta Pharm Hung. 2013. PMID: 23926649 Hungarian.
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.
Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L. Győrffy B, et al. Among authors: orfi l. Mol Oncol. 2014 May;8(3):508-19. doi: 10.1016/j.molonc.2013.12.018. Epub 2014 Jan 5. Mol Oncol. 2014. PMID: 24462521 Free PMC article.
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.
Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G. Szokol B, et al. Among authors: orfi z, orfi l. ACS Med Chem Lett. 2014 Jan 30;5(4):298-303. doi: 10.1021/ml4003309. eCollection 2014 Apr 10. ACS Med Chem Lett. 2014. PMID: 24900830 Free PMC article.
Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z, Balogh M, Bánhegyi P, Boros S, Breza N, Dobos J, Fábián M, Horváth Z, Illyés E, Markó P, Sipos A, Szántai-Kis C, Szokol B, Őrfi L. Czudor Z, et al. Among authors: orfi l. Bioorg Med Chem Lett. 2018 Feb 15;28(4):769-773. doi: 10.1016/j.bmcl.2018.01.002. Epub 2018 Jan 2. Bioorg Med Chem Lett. 2018. PMID: 29329658
120 results